Nidacon International AB

Nidacon International AB specializes in spermatozoa/semen motility medium supplements. These products are laboratory reagents designed to improve the assessment of sperm motility and quality during reproductive health evaluations. The focus is on creating controlled conditions for accurate semen analysis, which is critical for fertility testing and research.

Nidacon International AB is based in the United States, which means its devices must comply with U.S. regulatory requirements. The company’s products are listed in the FDA’s Unique Device Identifier (UDI) system, demonstrating their registration with the FDA. Classification under Class I or Class II determines the level of regulatory scrutiny, with Class II devices requiring additional validation for safety and performance.

Nidacon International AB’s devices are included in the FDA’s Unique Device Identifier (UDI) system, a central registry for tracking medical devices in the U.S. This listing ensures traceability and transparency for healthcare providers, laboratories, and regulatory authorities. The UDI system is mandatory for Class II devices and voluntary for Class I, but inclusion confirms the devices meet FDA registration requirements.

Nidacon International AB’s devices fall into Class I or Class II classifications, determined by their risk level and intended use. Class I devices, like some motility medium supplements, generally pose minimal risk and require general controls (e.g., proper labeling, manufacturing practices). Class II devices involve moderate risk and may require additional performance standards or post-market surveillance to ensure safety and effectiveness. Classification is based on factors like the device’s purpose, potential hazards, and clinical impact.